Affiliations: [a] Department of Gynecology and Obstetrics, Stanford University of Medicine, Stanford, CA, USA | [b] Department of Obstetrics and Gynecology, University of California Davis School of Medicine, Sacramento, CA, USA
Note: [] Present address of Michelle S. Glasky: Department of Pathology, University of Southern California School of Medicine, Los Angeles, CA 90033, USA.
Note: [] Address reprint requests to Dr. Nelson N.H. Teng, Department of Gynecology and Obstetrics, Stanford University School of Medicine, Stanford, CA 94305, USA.
Abstract: A human monoclonal antibody (MAb), MS2B6, produced from splenocytes isolated from a patient with advanced papillary serous cystadenocarcinoma of the ovary, defines a unique human tumor-associated antigen. This antigen, EA2B6 (epithelial antigen 2B6), is expressed in a tissue-restricted manner on cultured and fresh human adenocarcinomas and some normal glandular epithelial tissues. EA2B6 is a 38–48 kD protein antigen that co-fractionates with the nuclear matrix–intermediate filament scaffold of simple glandular epithelial tissues. EA2B6 is a molecule with restricted solubility, and in vitro antigen-antibody binding is dependent on the antigen being presented on a solid support. To determine if EA2B6 is a cytokeratin, competition studies were undertaken with several cytokeratin-specific murine monoclonal antibodies. None of these antibodies inhibited the binding of human MAb MS2B6 to partially purified EA2B6. Less than 1% of HT29 colon adenocarcinoma cells and fresh ovarian adenocarcinoma ascites cells express EA2B6 on their surface. The majority of EA2B6 is intracellular. Because of the restricted tissue distribution of this antigen and stability of the antibody, we believe MS2B6 is a good candidate for MAb-mediated diagnosis and therapy of human adenocarcinomas.
